{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:35:46Z","timestamp":1781188546045,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014841","name":"medac","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014841","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To identify biomarkers at the gene expression level to predict response to methotrexate (MTX) in patients with rheumatoid arthritis (RA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>MTX-na\u00efve patients with RA were started on MTX and followed up over three months. The disease activity score 28 (DAS28) was used to classify patients into responders and non-responders. Genome-wide gene expression analysis was performed in CD4\u2009+\u2009and CD14\u2009+\u2009mononuclear cells sampled from whole blood at baseline to identify differentially expressed genes in responders versus non-responders. Gene selection methods and prediction modelling obtained the most relevant differentially expressed genes. A logistic regression prediction model was subsequently constructed and validated via bootstrapping. The area under the receiver operating characteristic (AUC) curve was calculated to judge model quality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventy-nine patients with RA (53.4\u2009\u00b1\u200913.9 years, 74.7% females) were enrolled, and 70 finished the study with a documented treatment EULAR response (77.1% responders). Forty-six differentially expressed genes were found. The most promising genes were KRTAP4-11, LOC101927584, and PECAM1 in CD4\u2009+\u2009cells and PSMD5 and ID1 in CD14\u2009+\u2009cells. The final prediction model using these genes reached an AUC of 90%; the validation set\u2019s AUC was 82%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our prediction model constructed via genome-wide gene expression analysis in CD4\u2009+\u2009and CD14\u2009+\u2009mononuclear cells yielded excellent predictions. Our findings necessitate confirmation in other cohorts of MTX-na\u00efve RA patients. Especially if used in conjunction with previously identified clinical and laboratory (bio)markers, our results could help predict response to MTX in RA to guide treatment decisions.<\/jats:p>\n                <jats:p><jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>Patients with rheumatoid arthritis may or may not respond to treatment with methotrexate, which is the recommended first-line drug in guidelines around the world.<\/jats:italic>\u2022 <jats:italic>In non-responders, valuable time is lost until second-line treatments are started.<\/jats:italic>\u2022 <jats:italic>This study aimed at predicting response to methotrexate by identifying differentially expressed genes from peripheral blood samples.<\/jats:italic>\u2022 <jats:italic>The final prediction model yielded excellent prognostic values, but validation in other cohorts is necessary to corroborate these findings.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-023-06814-2","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T20:01:56Z","timestamp":1700251316000},"page":"511-519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Identification of gene expression biomarkers to predict clinical response to methotrexate in patients with rheumatoid arthritis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3456-0597","authenticated-orcid":false,"given":"Andriko","family":"Palmowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Strehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Pfeiffenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"H\u00e4upl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Schad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Kallarackal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Prothmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Dammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Gaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Buttgereit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"key":"6814_CR1","first-page":"16","volume":"124","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME (2013) Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc 124:16\u201325","journal-title":"Trans Am Clin Climatol Assoc"},{"issue":"6","key":"6814_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"6814_CR3","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St. Clair EW, Arayssi T, Carandang K et al (2021) American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res 73(7):924\u201339. https:\/\/doi.org\/10.1002\/acr.24596","journal-title":"Arthritis Care Res"},{"key":"6814_CR4","unstructured":"Deutsches Rheumaforschungszentrum: Daten der Kerndokumentation 2019. https:\/\/www.drfz.de\/wp-content\/uploads\/ergebnisse-standardprasentation-2019.pdf (2019). Accessed January 26th 2022"},{"issue":"1","key":"6814_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1741-7015-11-17","volume":"11","author":"VC Rom\u00e3o","year":"2013","unstructured":"Rom\u00e3o VC, Canh\u00e3o H, Fonseca JE (2013) Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? BMC Med 11(1):17. https:\/\/doi.org\/10.1186\/1741-7015-11-17","journal-title":"BMC Med"},{"issue":"1","key":"6814_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13075-016-1216-6","volume":"19","author":"M Tsukamoto","year":"2017","unstructured":"Tsukamoto M, Seta N, Yoshimoto K, Suzuki K, Yamaoka K, Takeuchi T (2017) CD14(bright)CD16+ intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis. Arthritis Res Ther 19(1):28. https:\/\/doi.org\/10.1186\/s13075-016-1216-6","journal-title":"Arthritis Res Ther"},{"key":"6814_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12967-014-0375-y","volume":"13","author":"L Chara","year":"2015","unstructured":"Chara L, S\u00e1nchez-Atrio A, P\u00e9rez A, Cuende E, Albarr\u00e1n F, Turri\u00f3n A et al (2015) The number of circulating monocytes as biomarkers of the clinical response to methotrexate in untreated patients with rheumatoid arthritis. J Transl Med 13:2. https:\/\/doi.org\/10.1186\/s12967-014-0375-y","journal-title":"J Transl Med"},{"issue":"12","key":"6814_CR8","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/art.1780351209","volume":"35","author":"R Thomas","year":"1992","unstructured":"Thomas R, McIlraith M, Davis LS, Lipsky PE (1992) Rheumatoid synovium is enriched in CD45RBdim mature memory T cells that are potent helpers for B cell differentiation. Arthritis Rheum 35(12):1455\u20131465. https:\/\/doi.org\/10.1002\/art.1780351209","journal-title":"Arthritis Rheum"},{"issue":"9","key":"6814_CR9","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569\u20132581. https:\/\/doi.org\/10.1002\/art.27584","journal-title":"Arthritis Rheum"},{"issue":"1","key":"6814_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"AM van Gestel","year":"1993","unstructured":"van Gestel AM, Prevoo ML, van\u2019t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1993) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria. Arthritis Rheum 39(1):34\u201340. https:\/\/doi.org\/10.1002\/art.1780390105","journal-title":"Arthritis Rheum"},{"issue":"1","key":"6814_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6814_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13075-018-1645-5","volume":"20","author":"JC Sergeant","year":"2018","unstructured":"Sergeant JC, Hyrich KL, Anderson J, Kopec-Harding K, Hope HF, Symmons DPM et al (2018) Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). Arthritis Res Ther 20(1):147. https:\/\/doi.org\/10.1186\/s13075-018-1645-5","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"6814_CR13","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1002\/art.22640","volume":"56","author":"JAM Wessels","year":"2007","unstructured":"Wessels JAM, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF et al (2007) A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 56(6):1765\u20131775. https:\/\/doi.org\/10.1002\/art.22640","journal-title":"Arthritis Rheum"},{"key":"6814_CR14","doi-asserted-by":"publisher","first-page":"368681","DOI":"10.1155\/2014\/368681","volume":"2014","author":"A Lima","year":"2014","unstructured":"Lima A, Monteiro J, Bernardes M, Sousa H, Azevedo R, Seabra V et al (2014) Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of <i>MTHFR<\/i> rs1801133 and <i>ATIC<\/i> rs4673993 polymorphisms. Biomed Res Int 2014:368681. https:\/\/doi.org\/10.1155\/2014\/368681","journal-title":"Biomed Res Int"},{"issue":"2","key":"6814_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2217\/pgs-2018-0144","volume":"20","author":"F Eektimmerman","year":"2019","unstructured":"Eektimmerman F, Allaart CF, Hazes JMW, Madhar MB, den Broeder AA, Fransen J et al (2019) Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients. Pharmacogenomics 20(2):85\u201393. https:\/\/doi.org\/10.2217\/pgs-2018-0144","journal-title":"Pharmacogenomics"},{"key":"6814_CR16","doi-asserted-by":"publisher","unstructured":"Myasoedova E, Athreya AP, Crowson CS, Davis Iii JM, Warrington KJ, Walchak RC, et al. (2021) Towards individualized prediction of response to methotrexate in early rheumatoid arthritis: a pharmacogenomics-driven machine learning approach. Arthritis Care Res 74(6):879\u2013888.\u00a0https:\/\/doi.org\/10.1002\/acr.24834","DOI":"10.1002\/acr.24834"},{"key":"6814_CR17","doi-asserted-by":"publisher","unstructured":"Hambardzumyan K, Bolce RJ, Wallman JK, van Vollenhoven RF, Saevarsdottir S (2019) Serum biomarkers for prediction of response to methotrexate monotherapy in early rheumatoid arthritis: results from the SWEFOT trial. J Rheumatol 46(6):555\u2013563. https:\/\/doi.org\/10.3899\/jrheum.180537","DOI":"10.3899\/jrheum.180537"},{"issue":"3","key":"6814_CR18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2214\/ajr.11.6798","volume":"197","author":"EL Rowbotham","year":"2011","unstructured":"Rowbotham EL, Grainger AJ (2011) Rheumatoid arthritis: ultrasound versus MRI. Am J Roentgenol 197(3):541\u2013546. https:\/\/doi.org\/10.2214\/ajr.11.6798","journal-title":"Am J Roentgenol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06814-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06814-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06814-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T16:21:21Z","timestamp":1704730881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06814-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["6814"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06814-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,17]]},"assertion":[{"value":"2 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study PreTheraX and the study protocol was approved by the ethics committees (April 15<sup>th<\/sup>, 2014; EA1\/073\/14) and institutional review boards. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FB reports receiving honoraria and grant\/study support from medac, Hexal, and Pfizer. MS and JK have received fees for service and consulting from Charite and medac. AB is an employee of medac GmbH. The other authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}